Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 1,591–1,600 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1591

    Medicine slug
    dabigatran-etexilate
    Medicine name
    Dabigatran Etexilate
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    6
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Figure 3.1 Effect of P-gp Inhibitor or Inducer (rifampicin) Drugs on Peak and Total Exposure to Dabigatran (Cmax and AUC).
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      The Perpetrator and Dabigatran Etexilate Dosage and Dosage Frequency are given as well as the Time of Perpetrator Dosage in Relation to Dabigatran Etexilate Dosage (Time Difference) Figure 3.2 Effect of Non-P-gp Inhibitor or Inducer, Other Drugs, on Peak and Total Exposure to Dabigatran (C max and AUC).
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Impact of Dabigatran on Other Drugs In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine. dabigartanfigure31 dabigartanfigure32
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Figure 3.1 Effect of P-gp Inhibitor or Inducer (rifampicin) Drugs on Peak and Total Exposure to Dabigatran (Cmax and AUC).
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      The Perpetrator and Dabigatran Etexilate Dosage and Dosage Frequency are given as well as the Time of Perpetrator Dosage in Relation to Dabigatran Etexilate Dosage (Time Difference) Figure 3.2 Effect of Non-P-gp Inhibitor or Inducer, Other Drugs, on Peak and Total Exposure to Dabigatran (C max and AUC).
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Impact of Dabigatran on Other Drugs In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine. dabigartanfigure31 dabigartanfigure32

  2. Projected row 1592

    Medicine slug
    dabigatran-etexilate
    Medicine name
    Dabigatran Etexilate
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Dabigatran etexilate is a substrate of the efflux transporter P-gp.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)

      Dabigatran Etexilate label

      Version not recorded · Effective date not recorded

      Dabigatran etexilate is a substrate of the efflux transporter P-gp.

  3. Projected row 1593

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    BCRP
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Dabrafenib and desmethyl-dabrafenib are inhibitors of OCT2 and BCRP in vitro.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Dabrafenib and desmethyl-dabrafenib are inhibitors of OCT2 and BCRP in vitro.

  4. Projected row 1594

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    BCRP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Transporters on Dabrafenib: Dabrafenib and its metabolites, hydroxyl-dabrafenib and desmethyl-dabrafenib, are substrates of human P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) but are not substrates of organic cation transporter (OCT1) or organic anion transporting polypeptide (OATP1A2, OATP1B1, OATP1B3, OATP2B1) in vitro.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Transporters on Dabrafenib: Dabrafenib and its metabolites, hydroxyl-dabrafenib and desmethyl-dabrafenib, are substrates of human P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) but are not substrates of organic cation transporter (OCT1) or organic anion transporting polypeptide (OATP1A2, OATP1B1, OATP1B3, OATP2B1) in vitro.

  5. Projected row 1595

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP1A2
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 150 mg twice daily for 15 days and a single dose of warfarin decreased the AUC of S-warfarin (a CYP2C9 substrate) by 37% and the AUC of R-warfarin (CYP3A4/CYP1A2 substrate) by 33%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 150 mg twice daily for 15 days and a single dose of warfarin decreased the AUC of S-warfarin (a CYP2C9 substrate) by 37% and the AUC of R-warfarin (CYP3A4/CYP1A2 substrate) by 33%.

  6. Projected row 1596

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP2B6
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      In vitro data demonstrate that dabrafenib is an inducer of CYP3A4 and CYP2B6 via activation of the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) nuclear receptors.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      In vitro data demonstrate that dabrafenib is an inducer of CYP3A4 and CYP2B6 via activation of the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) nuclear receptors.

  7. Projected row 1597

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP2C8
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Strong Inhibitors of CYP3A4 or CYP2C8 on Dabrafenib: Coadministration of TAFINLAR 75 mg twice daily and ketoconazole (a strong CYP3A4 inhibitor) for 4 days increased dabrafenib AUC by 71%, hydroxy-dabrafenib AUC by 82%, and desmethyl-dabrafenib AUC by 68%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Strong Inhibitors of CYP3A4 or CYP2C8 on Dabrafenib: Coadministration of TAFINLAR 75 mg twice daily and ketoconazole (a strong CYP3A4 inhibitor) for 4 days increased dabrafenib AUC by 71%, hydroxy-dabrafenib AUC by 82%, and desmethyl-dabrafenib AUC by 68%.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 75 mg twice daily and gemfibrozil (a strong CYP2C8 inhibitor) for 4 days increased dabrafenib AUC by 47%, with no change in the AUC of dabrafenib metabolites.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 75 mg twice daily and gemfibrozil (a strong CYP2C8 inhibitor) for 4 days increased dabrafenib AUC by 47%, with no change in the AUC of dabrafenib metabolites.

  8. Projected row 1598

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP2C8
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Metabolism The metabolism of dabrafenib is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-dabrafenib.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Strong Inducers of CYP3A4 or Moderate Inducers of CYP2C8 on Dabrafenib: Coadministration of TAFINLAR 150 mg twice daily and rifampin (a strong CYP3A4 and moderate CYP2C8 inducer) for 10 days decreased dabrafenib AUC by 34% and desmethyl-dabrafenib AUC by 30%, and had no effect on hydroxy-dabrafenib AUC.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Metabolism The metabolism of dabrafenib is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-dabrafenib.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Effect of Strong Inducers of CYP3A4 or Moderate Inducers of CYP2C8 on Dabrafenib: Coadministration of TAFINLAR 150 mg twice daily and rifampin (a strong CYP3A4 and moderate CYP2C8 inducer) for 10 days decreased dabrafenib AUC by 34% and desmethyl-dabrafenib AUC by 30%, and had no effect on hydroxy-dabrafenib AUC.

  9. Projected row 1599

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP2C9
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 150 mg twice daily for 15 days and a single dose of warfarin decreased the AUC of S-warfarin (a CYP2C9 substrate) by 37% and the AUC of R-warfarin (CYP3A4/CYP1A2 substrate) by 33%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      Coadministration of TAFINLAR 150 mg twice daily for 15 days and a single dose of warfarin decreased the AUC of S-warfarin (a CYP2C9 substrate) by 37% and the AUC of R-warfarin (CYP3A4/CYP1A2 substrate) by 33%.

  10. Projected row 1600

    Medicine slug
    dabrafenib
    Medicine name
    Dabrafenib
    Enzyme or transporter
    CYP3A4
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      In vitro data demonstrate that dabrafenib is an inducer of CYP3A4 and CYP2B6 via activation of the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) nuclear receptors.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea (opens source in a new tab)

      Dabrafenib label

      Version not recorded · Effective date not recorded

      In vitro data demonstrate that dabrafenib is an inducer of CYP3A4 and CYP2B6 via activation of the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) nuclear receptors.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1590

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy